Publications by authors named "Maria Zalath"

Claim this Profile
S
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, Robert M Sharkey, Serengulam V Govindan

Oncotarget· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Thomas M Cardillo, Diane L Rossi, Maria B Zalath, Donglin Liu, Roberto Arrojo

Oncotarget· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Thomas M Cardillo, Serengulam V Govindan, Maria B Zalath, Diane L Rossi, Yang Wang

Mol Cancer Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Chien-Hsing Chang, Yang Wang, Maria Zalath, Donglin Liu, Thomas M Cardillo

Mol Cancer Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Rhona Stein, Mitchell R Smith, Susan Chen, Maria Zalath, David M Goldenberg

Clin Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis